Skip to contentX
Xenon Pharmaceuticals Inc.
X
XENEXenon Pharmaceuticals Inc. Q2 2025 · 10-Q
Revenue$0.00$0.00— vs Q2 2024 Net Income-$84.71M-$84.71MN/M vs Q2 2024 EPS Diluted-$1.07-$1.07N/M vs Q2 2024 Operating Income-$94,229,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Xenon Pharmaceuticals Inc. · CIK 1582313 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$64,390,000N/M ended Jun 30, 2025 · filed Aug 11, 2025 · 42 d after period end